GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

BRISBANE, CALIFORNIA, March 26, 2024 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced fourth quarter and full-year 2023 results for the period ended December 31, 2023.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks